UNITED STATES SECURITIES AND EXCHANGE COMMISSION November 23, 2015

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Arbutus Biopharma Corporation

File No. 001-34949 - CF#33124

Arbutus Biopharma Corporation formerly Tekmira Pharmaceuticals Corporation submitted an application under Rule 24b-2 confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 5, 2015.

Based on representations by Arbutus Biopharma Corporation that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1 through November 5, 2025 Exhibit 10.2 through November 5, 2025

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary